Kyverna Therapeutics Inc. (KYTX)
| Bid | 2.59 |
| Market Cap | 112.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -110.7M |
| EPS (ttm) | -2.96 |
| PE Ratio (ttm) | -0.88 |
| Forward PE | -0.98 |
| Analyst | Buy |
| Ask | 3.02 |
| Volume | 276,493 |
| Avg. Volume (20D) | 373,113 |
| Open | 2.87 |
| Previous Close | 2.84 |
| Day's Range | 2.60 - 2.81 |
| 52-Week Range | 2.60 - 30.60 |
| Beta | 2.66 |
About KYTX
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company...
Analyst Forecast
According to 5 analyst ratings, the average rating for KYTX stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 819.54% from the latest price.
3 weeks ago · accessnewswire.com
February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - KYTXNEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal se...